Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt?

Right now, Incyte stock is heavily dependent on its blockbuster drug Jakafi, which is used to treat bone marrow diseases, including cancer. In the first half of this year, it accounted for nearly 90% of all revenues. That kind of narrow revenue-dependence can be frightening to investors.

But there are at least two reasons not to worry about this.